Al-Moamary Mohamed S, Alhaider Sami A, Alangari Abdullah A, Idrees Majdy M, Zeitouni Mohammed O, Al Ghobain Mohammed O, Alanazi Abdullah F, Al-Harbi Adel S, Yousef Abdullah A, Alorainy Hassan S, Al-Hajjaj Mohamed S
Department of Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Ann Thorac Med. 2021 Jan-Mar;16(1):4-56. doi: 10.4103/atm.ATM_697_20. Epub 2021 Jan 14.
The Saudi Initiative for Asthma 2021 (SINA-2021) is the fifth version of asthma guidelines for the diagnosis and management of asthma for adults and children, which is developed by the SINA group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up to date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is aligned for age groups: adults, adolescents, children aged 5-12 years, and children aged less than 5 years. SINA guidelines have focused more on personalized approaches reflecting better understanding of disease heterogeneity with the integration of recommendations related to biologic agents, evidence-based updates on treatment, and the role of immunotherapy in management. Medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and the current situation at national and regional levels. There is also an emphasis on patient-doctor partnership in the management that also includes a self-management plan.
《2021年沙特哮喘倡议》(SINA - 2021)是沙特胸科学会下属的SINA小组制定的成人及儿童哮喘诊断与管理指南的第五版。SINA的主要目标是制定出与时俱进、易于理解且便于治疗哮喘患者的医护人员使用的指南。为推动实现哮喘管理目标,SINA小组方法主要基于对成人和儿童症状控制及风险的评估。哮喘管理方法针对不同年龄组进行了调整:成人、青少年、5至12岁儿童以及小于5岁儿童。SINA指南更侧重于个性化方法,体现了对疾病异质性的更好理解,整合了与生物制剂相关的建议、基于证据的治疗更新以及免疫疗法在管理中的作用。药物附录也根据最新证据、现有药物的新适应症和新药物进行了更新。这些指南是基于现有证据、当地文献以及国家和地区层面的现状制定的。管理中还强调了医患合作,其中包括自我管理计划。